Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday, soared 7.09% from the previous trading day, before settling in for the closing price of $12.7. Within the past 52 weeks, OCUL’s price has moved between $5.78 and $13.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 8.51% over the last five years. The company achieved an average annual earnings per share of -25.34%. With a float of $145.76 million, this company’s outstanding shares have now reached $172.93 million.
Ocular Therapeutix Inc (OCUL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ocular Therapeutix Inc is 16.41%, while institutional ownership is 79.36%. The most recent insider transaction that took place on Sep 02 ’25, was worth 13,250. In this transaction an insider of this company sold 1,066 shares at a rate of $12.43, taking the stock ownership to the 308,807 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Officer proposed sale 1,066 for $12.43, making the entire transaction worth $13,245.
Ocular Therapeutix Inc (OCUL) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.22 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.21) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.31% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Ocular Therapeutix Inc (OCUL) is currently performing well based on its current performance indicators. A quick ratio of 10.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.28, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.49 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Analysing the last 5-days average volume posted by the [Ocular Therapeutix Inc, OCUL], we can find that recorded value of 3.43 million was better than the volume posted last year of 1.84 million. As of the previous 9 days, the stock’s Stochastic %D was 78.98%.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 96.51%, which indicates a significant increase from 88.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.56 in the past 14 days, which was higher than the 0.52 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.62, while its 200-day Moving Average is $8.89. Now, the first resistance to watch is $14.08. This is followed by the second major resistance level at $14.55. The third major resistance level sits at $15.26. If the price goes on to break the first support level at $12.90, it is likely to go to the next support level at $12.19. Should the price break the second support level, the third support level stands at $11.72.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
Market capitalization of the company is 2.37 billion based on 173,995K outstanding shares. Right now, sales total 63,720 K and income totals -193,510 K. The company made 13,460 K in profit during its latest quarter, and -67,810 K in sales during its previous quarter.
